Pediatric Alport Syndrome 

  • Author: Prasad Devarajan, MD; Chief Editor: Craig B Langman, MD   more...
 
Updated: Nov 29, 2011
 

Background

Alport syndrome encompasses a group of heterogeneous inherited disorders involving the basement membranes of the kidney and frequently involving the cochlea and the eye. These disorders are the result of mutations in type IV collagen genes. The mode of inheritance is X-linked in 80%, autosomal recessive in 15%, and autosomal dominant in about 5% of individuals with Alport syndrome.

In 1927, Alport first described the combination of progressive hereditary nephritis with sensorineural deafness. The presence of 3 of the following 4 proposed diagnostic criteria establishes the diagnosis of Alport syndrome:

  1. Family history of hematuria, progressing mostly in males to end-stage renal disease (ESRD)
  2. Thickening and splitting of the glomerular basement membrane detected by electron microscopy
  3. Progressive, high-frequency, sensorineural deafness
  4. Anterior lenticonus and perimacular flecks

Children with Alport syndrome may initially present with only persistent hematuria and a family history of hematuria. Auditory or ocular manifestations may appear later in life. The typical changes of the glomerular basement membrane are also age dependent and may be absent from initial biopsy samples obtained from young children with Alport syndrome.

Next

Pathophysiology

Recent advances in study of the cellular and molecular biology of proteins of the basement membrane have been instrumental in elucidating the pathophysiology of Alport syndrome.[1, 2, 3] Basement membranes are sheetlike structures that support endothelial and epithelial cells. They are composed of various proteins that these cell secrete, including a network of type IV collagen. The family of type IV collagens consists of 6 chains designated a1 through a6(IV) that share a collagenous domain and a carboxy-terminal noncollagenous (NC1) domain.

The genes for type IV collagen are distributed in pairs on 3 chromosomes. The genes COL4A1 and COL4A2 on chromosome 13 encode for the a1 and a2 changes, COL4A3 and COL4A4 on chromosome 2 encode for the a3 and a4 chains, and COL4A5 and COL4A6 on the X chromosome encode for a5 and a6. The a1 and a2 chains are present in all basement membranes. The a3 and a4 chains are restricted to the basement membranes of the glomerulus, cochlea, and eye. The a5 chain is expressed in the glomerulus, cochlea, eye, and epidermis.

Patients with Alport syndrome have mutations in COL4A3, COL4A4, or COL4A5, with consequent abnormalities in the basement membranes of the glomerulus (leading to hematuria, glomerulosclerosis, and ESRD), cochlea (causing deafness), and eye (resulting in lenticonus and perimacular flecks).

Children with Alport syndrome usually have normal development and intelligence. However, a rare contiguous gene-deletion syndrome involving chromosome Xq22.3 has been described; this has been named Alport syndrome and mental retardation (ATS-MR).[4]

Previous
Next

Epidemiology

Frequency

United States

The genetic frequency for Alport syndrome is estimated to be 1 case in 5000 population. According to the 2007 annual data report of the United States Renal Data System, Alport syndrome accounts for approximately 2.1% of pediatric patients with ESRD.[5] More than 85% of these patients are males.

International

In Europe, Alport syndrome may be responsible for as many as 2.3% of cases of ESRD.

Mortality/Morbidity

Male individuals with X-linked Alport syndrome and people of both sexes with autosomal recessive disease have increasing proteinuria, hypertension, progression to ESRD, and hearing loss during the second to fourth decades of life. Male patients with the typical X-linked disease have a renal half-life of about 25 years, and about 90% develop ESRD before 40 years of age.

In female patients, progression to ESRD was previously thought to be rare. However, observations have shown that as many as 12% of female patients also develop ESRD by age 40 years; this rate increases to 30% by age 60 years and 40% by age 80 years. Among female patients, risk factors for progression to ESRD include the degree of proteinuria and hearing loss.

Race

No racial predilection is reported.

Sex

The common X-linked form of Alport syndrome leading to ESRD predominantly affects male individuals. Many female patients with X-linked Alport syndrome have mild disease, but studies have shown significant renal morbidity in female patients who develop proteinuria and hearing loss.[6, 7] The uncommon autosomal recessive form of Alport syndrome equally affects both sexes (see Mortality/Morbidity).

Age

Most patients with Alport syndrome present with persistent microscopic hematuria and episodic gross hematuria during the first 2 decades of life. Two clinical subtypes of Alport syndrome have been distinguished on the basis of their rates of progression. The first is a juvenile type in which ESRD occurs when an individual is aged approximately 20 years; its course is fairly constant within a given family. The second is an adult variety in which ESRD occurs when the individual is older than 40 years. This form has notable intrakindred variability. Also see Mortality/Morbidity.

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

Prasad Devarajan, MD  Louise M Williams Endowed Chair in Pediatrics, Professor of Pediatrics and Developmental Biology, Director of Nephrology and Hypertension, Director of Clinical Nephrology Laboratories, CEO of Dialysis Unit, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine

Prasad Devarajan, MD is a member of the following medical societies: American Heart Association, American Society of Nephrology, American Society of Pediatric Nephrology, National Kidney Foundation, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Uri S Alon, MD  Director of Bone and Mineral Disorders Clinic and Renal Research Laboratory, Children's Mercy Hospital of Kansas City; Professor, Department of Pediatrics, Division of Pediatric Nephrology, University of Missouri-Kansas City School of Medicine

Uri S Alon, MD is a member of the following medical societies: American Federation for Medical Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Luther Travis, MD  Professor Emeritus, Departments of Pediatrics, Nephrology and Diabetes, University of Texas Medical Branch School of Medicine

Luther Travis, MD is a member of the following medical societies: Alpha Omega Alpha, American Federation for Medical Research, International Society of Nephrology, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Howard Trachtman, MD  Program Director, Pediatrics Research, Schneider Children's Hospital, Department of Pediatrics, Division of Nephrology, Professor, Albert Einstein College of Medicine

Howard Trachtman, MD is a member of the following medical societies: American Society of Hypertension, American Society of Nephrology, American Society of Pediatric Nephrology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Craig B Langman, MD  The Isaac A Abt, MD, Professor of Kidney Diseases, Northwestern University, The Feinberg School of Medicine; Division Head of Kidney Diseases, Children's Memorial Hospital

Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, and International Society of Nephrology

Disclosure: NIH Grant/research funds None; Raptor Pharmaceuticals, Inc Grant/research funds None; Alexion Pharmaceuticals, Inc. Grant/research funds None

References

  1. Kashtan CE. Familial hematuria. Pediatr Nephrol. Oct 2007;[Medline].

  2. Gross O. Understanding renal disorders as systemic diseases: the fascinating world of basement membranes beyond the glomerulus. Nephrol Dial Transplant. Jun 2008;23(6):1823-5. [Medline].

  3. Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol. Jan 2008;4(1):24-37. [Medline].

  4. Meloni I, Vitelli F, Pucci L, et al. Alport syndrome and mental retardation: clinical and genetic dissection of the contiguous gene deletion syndrome in Xq22.3 (ATS-MR). J Med Genet. May 2002;39(5):359-65. [Medline].

  5. United States Renal Data System. Annual Data Report 2008. USRDS - ADR. Available at http://www.usrds.org/adr.htm. Accessed September 20, 2008.

  6. Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol. Oct 2003;14(10):2603-10. [Medline].

  7. Rheault MN. Women and Alport syndrome. Pediatr Nephrol. Mar 5 2011;[Medline].

  8. Gupta A, Ramesh Babu K, Srinivasan R, Mohanty D. Clear lens extraction in Alport syndrome with combined anterior and posterior lenticonus or ruptured anterior lens capsule. J Cataract Refract Surg. Nov 2011;37(11):2075-8. [Medline].

  9. Jain C, Malik VK, Kamboj R, Kumar S, Kumar S, Jain K. Alport Syndrome: case report and review of ocular manifestations. Nepal J Ophthalmol. Jul 2011;3(6):118-90. [Medline].

  10. Patey-Mariaud de Serre N, Garfa M, Bessieres B, Noel LH, Knebelmann B. Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients. Kidney Int. Aug 2007;72(4):512-6. [Medline].

  11. Gubler MC. Diagnosis of Alport Syndrome without biopsy?. Pediatr Nephrol. May/2007;22:621-5. [Medline].

  12. Artuso R, Fallerini C, Dosa L, Scionti F, Clementi M, Garosi G, et al. Advances in Alport syndrome diagnosis using next-generation sequencing. Eur J Hum Genet. Sep 7 2011;[Medline].

  13. Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. Jan 2007;22(1):57-63. [Medline].

  14. Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant. Sept 2006;10:651-7. [Medline].

  15. Mojahedi MJ, Hekmat R, Ahmadnia H. Kidney transplantation in patients with alport syndrome. Urol J. Fall 2007;4(4):234-7. [Medline].

  16. Callis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int. Mar 1999;55(3):1051-6. [Medline].

  17. Anker MC, Arnemann J, Neumann K, et al. Alport syndrome with diffuse leiomyomatosis. Am J Med Genet A. Jun 15 2003;119(3):381-5. [Medline].

  18. Cohen EP, Lemann J Jr. In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression. Am J Kidney Dis. Feb 1996;27(2):199-203. [Medline].

  19. Copelovitch L, Kaplan BS. Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical?. Pediatr Nephrol. Apr 2006;21(4):455-6. [Medline].

  20. Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol. Aug 2005;130(4):620-7. [Medline].

  21. Ghiggeri GM, Caridi G, Magrini U, et al. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis. Jan 2003;41(1):95-104. [Medline].

  22. Gregory MC. Alport syndrome and thin basement membrane nephropathy: unraveling the tangled strands of type IV collagen. Kidney Int. Mar 2004;65(3):1109-10. [Medline].

  23. Gubler MC, Knebelmann B, Antignac C, et al. Inherited glomerular disease. In: Inherited glomerular disease. Pediatric Nephrology. 4th Edition. Williams & Wilkins; 1999:475-95.

  24. Heidet L, Arrondel C, Forestier L. Structure of the human type iv collagen gene col4a3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol. Jan 2001;12(1):97-106. [Medline].

  25. Hu A, Wang F, Sellers JR. Mutations in human nonmuscle myosin IIA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function. J Biol Chem. Nov 29 2002;277(48):46512-7. [Medline].

  26. Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol. Oct 2004;15(10):2514-27. [Medline].

  27. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med. Jun 19 2003;348(25):2543-56. [Medline].

  28. Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. Apr 2000;11(4):649-57. [Medline].

  29. Kashtan CE. Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr. Apr 2004;16(2):177-81. [Medline].

  30. Kashtan CE. Familial hematurias: what we know and what we don't. Pediatr Nephrol. Aug 2005;20(8):1027-35. [Medline].

  31. Longo I, Porcedda P, Mari F, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int. Jun 2002;61(6):1947-56. [Medline].

  32. Longo I, Scala E, Mari F, et al. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant. Mar 2006;21(3):665-71. [Medline].

  33. Martin P, Heiskari N, Zhou J, et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol. Dec 1998;9(12):2291-301. [Medline].

  34. Mazzucco G, Barsotti P, Muda AO, et al. Ultrastructural and immunohistochemical findings in Alport's syndrome: a study of 108 patients from 97 Italian families with particular emphasis on COL4A5 gene mutation correlations. J Am Soc Nephrol. Jun 1998;9(6):1023-31. [Medline].

  35. Meloni I, Muscettola M, Raynaud M, et al. FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation. Nat Genet. Apr 2002;30(4):436-40. [Medline].

  36. Nagel M, Nagorka S, Gross O. Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome. Hum Mutat. Jul 2005;26(1):60. [Medline].

  37. Pescucci C, Mari F, Longo I, et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int. May 2004;65(5):1598-603. [Medline].

  38. Pirson Y. Making the diagnosis of Alport's syndrome. Kidney Int. Aug 1999;56(2):760-75. [Medline].

  39. Proesmans W, Van Dyck M. Enalapril in children with Alport syndrome. Pediatr Nephrol. Mar 2004;19(3):271-5. [Medline].

  40. Slajpah M, Meglic A, Furlan P, Glavac D. The importance of non-invasive genetic analysis in the initial diagnostics of Alport syndrome in young patients. Pediatr Nephrol. Sep 2005;20(9):1260-4. [Medline].

  41. Takemura T, Yanagida H, Yagi K, et al. Alport syndrome and benign familial hematuria (thin basement membranedisease) in two brothers of a family with hematuria. Clin Nephrol. Sep 2003;60(3):195-200. [Medline].

  42. Toren A, Rozenfeld-Granot G, Rocca B. Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. Blood. Nov 15 2000;96(10):3447-51. [Medline].

  43. Wang F, Wang Y, Ding J, Yang J. Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts. Kidney Int. Apr 2005;67(4):1268-74. [Medline].

  44. White RH, Raafat F, Milford DV, et al. The Alport nephropathy: clinicopathological correlations. Pediatr Nephrol. Jul 2005;20(7):897-903. [Medline].

  45. Yachnin T, Iaina A, Schwartz D, Nakache R. The mother of an Alport's syndrome patient: a safe kidney donor?. Nephrol Dial Transplant. Apr 2002;17(4):683-4. [Medline].

 
Previous
Next
 
Electron micrograph from a patient with Alport syndrome revealing the typical splitting and splintering of the glomerular basement membrane (original magnification X3000). Courtesy of Glen S. Markowitz, MD, Department of Pathology, Columbia University College of Physicians and Surgeons, New York.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.